PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...
Steve Cohen’s billion-dollar spending spree hits a wall as underperforming stars and injury woes leave New York’s record-breaking $329 million payroll languishing at the bottom of the division.
Three of 5 (60%) patients on the LoVAS regimen relapsed compared with 2 of 16 (12.5%) on the PEXIVAS regimen. In most cases, relapses occurred early after treatment initiation.
To design safe clinical trials, it is crucial to better understand and predict gene editing outcomes in preclinical studies. Bence György and collaborators have shown that adeno-associated viruses ...
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely ...
SB Nation on MSN
Devils Re-Sign Nico Hischier to a 5-Year, $11.7M AAV contract
The Devils got their most important piece of offseason business done, agreeing to a new contract with Nico Hischier ...
Several quality attributes (QAs) must be monitored to ensure an effective and safe final product when developing adeno-associated virus (AAV) vectors as drug products. Thermal stability, aggregate ...
AskBio founder R. Jude Samulski talks about the evolution and future of AAV gene therapy following his company’s blockbuster acquisition by Bayer in 2020. R. Jude Samulski, PhD It is rare that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results